SOLIRIS (eculizumab): The first treatment specifically approved for PNH

SOLIRIS OneSource Program Overview

SOLIRIS OneSource Program OverviewNow there's OneSource for answers

The SOLIRIS OneSource™ program is a resource that provides information about PNH treatment support and ongoing access to SOLIRIS® (eculizumab) for patients. The program offers assistance in these ways:

  • Provides you with an Alexion Case Manager, a registered nurse who offers answers and help with practical issues around insurance, treatments and more
     
  • Can assist you in working with your insurance company and other funding sources
     
  • Can provide information if your own insurance does not cover SOLIRIS, or if you do not have insurance
     
  • Provides educational materials explaining PNH, SOLIRIS, and the OneSource program

Next: Alexion Case Managers

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.